NCT05719701View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

December 30, 2025

Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
DRUG

ICP-490

Several dose groups of ICP-490 are planned for the dose exploration.

DRUG

Dexamethasone

Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.

Trial Locations (6)

510120

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Unknown

RECRUITING

Peking University People's Hospital, Beijing

NOT_YET_RECRUITING

Henan Cancer Hosptital, Zhengzhou

NOT_YET_RECRUITING

Shengjing Hospital of China Medical University, Shenyang

NOT_YET_RECRUITING

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

NOT_YET_RECRUITING

The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY